To include your compound in the COVID-19 Resource Center, submit it here.

Astellas acquires build-to-buy Mitobridge

Astellas Pharma Inc. (Tokyo:4503) exercised an exclusive option to acquire mitochondrial disorder company Mitobridge Inc. (Cambridge, Mass.) for $225

Read the full 194 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE